Evidence map›Paper›PMID 36496409›Full record

ArticleNature communications2022

Mitochondrial dysfunction induces ALK5-SMAD2-mediated hypovascularization and arteriovenous malformations in mouse retinas.

Haifeng Zhang, Busu Li, Qunhua Huang, Francesc López-Giráldez, Yoshiaki Tanaka, Qun Lin, Sameet Mehta, Guilin Wang, Morven Graham, Xinran Liu and 4 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 2 countries.

Haifeng Zhang *Interdepartmental Program in Vascular Biology and Therapeutics, Department of Pathology, Yale University School of Medicine, New Haven, CT, USA.
Busu Li *Interdepartmental Program in Vascular Biology and Therapeutics, Department of Pathology, Yale University School of Medicine, New Haven, CT, USA.ORCID http://orcid.org/0000-0002-2937-129X
Qunhua Huang *Interdepartmental Program in Vascular Biology and Therapeutics, Department of Pathology, Yale University School of Medicine, New Haven, CT, USA.
Francesc López-GiráldezYale Center for Genomic Analysis, Department of Genetics, Yale University School of Medicine, New Haven, CT, USA.ORCID http://orcid.org/0000-0001-7476-9822
Yoshiaki TanakaYale Stem Cell Center, Department of Genetics, Yale University School of Medicine, New Haven, CT, USA.ORCID http://orcid.org/0000-0002-2078-9374
Qun LinInterdepartmental Program in Vascular Biology and Therapeutics, Department of Pathology, Yale University School of Medicine, New Haven, CT, USA.ORCID http://orcid.org/0000-0002-9629-5733
Sameet MehtaYale Center for Genomic Analysis, Department of Genetics, Yale University School of Medicine, New Haven, CT, USA.ORCID http://orcid.org/0000-0002-3029-3217
Guilin WangYale Center for Genomic Analysis, Department of Genetics, Yale University School of Medicine, New Haven, CT, USA.
Morven GrahamDepartment of Cell Biology, Yale University School of Medicine, New Haven, CT, USA.ORCID http://orcid.org/0000-0002-4375-3198
Xinran LiuDepartment of Cell Biology, Yale University School of Medicine, New Haven, CT, USA.
In-Hyun ParkYale Center for Genomic Analysis, Department of Genetics, Yale University School of Medicine, New Haven, CT, USA.ORCID http://orcid.org/0000-0001-7748-1293
Anne EichmannDepartment of Internal Medicine (Cardiology) and Cellular and Molecular Physiology, Yale University School of Medicine, New Haven, CT, USA.
Wang MinInterdepartmental Program in Vascular Biology and Therapeutics, Department of Pathology, Yale University School of Medicine, New Haven, CT, USA. mike.wang388@gmail.com.ORCID http://orcid.org/0000-0002-2479-6096
Jenny Huanjiao ZhouInterdepartmental Program in Vascular Biology and Therapeutics, Department of Pathology, Yale University School of Medicine, New Haven, CT, USA. Jenny.zhou@yale.edu.ORCID http://orcid.org/0000-0003-3071-9473
Yale University · USYale Cancer Center · US

Funding

Investigating the intracellular vesicle-mediated mechanism contributing to cerebral cavernous malformationR01HL157019 · NHLBI · YALE UNIVERSITY · PI ZHOU, JENNY HUANJIAO · 2021 to 2025
$2.1M
Investigating the role of mitochondrial dysfunction in the pathogenesis of retinal vascular diseasesR01EY033333 · NEI · YALE UNIVERSITY · PI Jenny Huanjiao Zhou · 2022 to 2026
$2.1M
Cancer Bioinformatics: Data analysis and method development for the Yale Cancer CenterR50CA265359 · NCI · YALE UNIVERSITY · PI Juan Francisco Lopez Giraldez · 2022 to 2026
$699k
NCI NIH HHS R50 CA265359NEI NIH HHS R01 EY033333NHLBI NIH HHS R01 HL157019
6 · The paper itself

Abstract

Although mitochondrial activity is critical for angiogenesis, its mechanism is not entirely clear. Here we show that mice with endothelial deficiency of any one of the three nuclear genes encoding for mitochondrial proteins, transcriptional factor (TFAM), respiratory complex IV component (COX10), or redox protein thioredoxin 2 (TRX2), exhibit retarded retinal vessel growth and arteriovenous malformations (AVM). Single-cell RNA-seq analyses indicate that retinal ECs from the three mutant mice have increased TGFβ signaling and altered gene expressions associated with vascular maturation and extracellular matrix, correlating with vascular malformation and increased basement membrane thickening in microvesels of mutant retinas. Mechanistic studies suggest that mitochondrial dysfunction from Tfam, Cox10, or Trx2 depletion induces a mitochondrial localization and MAPKs-mediated phosphorylation of SMAD2, leading to enhanced ALK5-SMAD2 signaling. Importantly, pharmacological blockade of ALK5 signaling or genetic deficiency of SMAD2 prevented retinal vessel growth retardation and AVM in all three mutant mice. Our studies uncover a novel mechanism whereby mitochondrial dysfunction via the ALK5-SMAD2 signaling induces retinal vascular malformations, and have therapeutic values for the alleviation of angiogenesis-associated human retinal diseases.

Indexed as

Arteriovenous MalformationsReceptor, Transforming Growth Factor-beta Type ISmad2 ProteinAlkyl and Aryl TransferasesAnimalsGene Expression RegulationMembrane ProteinsMiceMitochondriaPhosphorylationSignal TransductionTransforming Growth Factor betaAlkyl and Aryl TransferasesCOX10 protein, mouseMembrane ProteinsReceptor, Transforming Growth Factor-beta Type ISmad2 ProteinSmad2 protein, mouseTgfbr1 protein, mouseTransforming Growth Factor beta

Identifiers

PMID36496409
PMCPMC9741628
OpenAlexW4312060340

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.